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Atrial fibrillation is associated with increased
risk of perioperative stroke and death from
carotid endarterectomy
Nancy L. Harthun, MD,a and George J. Stukenborg, PhD,b Charlottesville, Va
Background:Carotid endarterectomy is performed in high volume in the United States. Identifying patients with a higher
risk of stroke and death after carotid endarterectomy can lead to modifications in care that would significantly reduce the
occurrence of these events. This study evaluates whether atrial fibrillation is significantly associated with an increased risk
of death or stroke for patients undergoing carotid endarterectomy.
Methods: This retrospective cohort study uses multivariable logistic regression analysis to assess the relationship between
atrial fibrillation and death and/or stroke after carotid endarterectomy. The study population is drawn from the National
Inpatient Sample, 2005. All patients with a primary carotid endarterectomy and diagnosis of stenosis of precerebral
arteries were included, except patients with concomitant open heart procedures. The main outcomes examined were
in-hospital death and stroke, adjusted for age, gender, symptomatic status, and for comorbid disease.
Results: Carotid endarterectomy was performed for 20,022 patients. Strokes occurred in 189 patients (0.94%), and death
occurred in 59 (0.29%). Patients with atrial fibrillation had significantly higher adjusted odds of stroke or death (odds
ratio  2.45; P < .0001).
Conclusion: Patients with atrial fibrillation have a substantially higher risk of stroke and death after carotid endarterec-
tomy. (J Vasc Surg 2010;51:330-6.)Carotid endarterectomy (CEA) is performed to lower
the risk of stroke among patients considered to be at risk
from carotid artery stenosis. Ironically, perioperative stroke
is one of the most common major complications of this
procedure. Approximately 100,000 CEAs are performed
annually in the United States.1 Adverse events are rare. The
percentage of patients who experience a stroke during the
perioperative period is between 0.7 to 1.5, and the percent-
age of perioperative death is approximately 0.5.2 However,
because of the high volume, CEA is responsible for 1000
strokes or deaths per year. Decreasing the adverse event
rates for this high volume procedure can meaningfully
improve patient outcomes in the population. The first step
in lowering this event rate would be to identify which
patients are at higher risk of stroke or death as a complica-
tion of the procedure.
There is little guidance available regarding which co-
morbid illnesses are potential contraindications for CEA,
and the identification of specific comorbid illness or com-
binations of comorbid illnesses that generate higher risk of
major adverse events after CEA has not been determined in
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330any systematic fashion. This type of determination is sub-
ject to the variation of individual clinical practices. Patients
with minimal or no comorbidities are frequently selected
for randomized controlled trials3-5 conducted to determine
the effects of the severity of the carotid stenosis and preop-
erative symptoms on outcomes of CEA. In fact, cardiac
arrhythmias were a specific exclusion factor for two of the
most well-known randomized controlled trials (Asymp-
tomatic Carotid Atherosclerosis Study [ACAS] and North
American Symptomatic Carotid Endarterectomy Trial,
[NASCET]).6,7 However, CEA is frequently performed in
elderly patients with concomitant multiple and severe co-
morbid diseases.8 This population is substantially different
from those typically enrolled in such trials, making exami-
nation of their outcomes important for continued improve-
ment of the application of CEA.
Chronic atrial fibrillation (AF) is a common comorbid
condition among CEA patients. Several prior studies have
documented a significantly increased risk of death or stroke
after CEA among patients with AF as a secondary find-
ing.9-11 A prior study of risk factors for perioperative stroke
or death, which includedmore than 6000 patients from the
Ontario Carotid Endarterectomy Registry, found that pa-
tients with AF had significantly higher odds of perioperative
death or stroke (odds ratio [OR]  1.75; P  .0011).9
Patients with AF have also been found to be at higher risk
for stroke or death in a study that examined the effect of
cholesterol-lowering agents on outcomes of CEA10 and in
a study that examined the effect of patient gender on CEA
outcomes.11
The objective of this study is to determine whether
patients with AF have an increased risk of perioperative
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patients undergoing the procedure in the United States.
METHODS
Data source. Data for this study are drawn from in-
patient hospital discharge abstracts collected for the
Healthcare Cost and Utilization Project (HCUP) 2005
National Inpatient Sample (NIS). The 2005 NIS includes
almost 8 million in-patient hospital discharge abstracts
collected for patients of all ages and all sources of insurance
who received in-patient care in 1054 nonfederal hospitals
in 37 states. Each discharge record includes a weight that
represents the relative proportion of the total U.S. hospital
patient population accounted for by that record.12 This
data set is broadly representative of individuals in the U.S.
population who were hospitalized during 2005, and it is
the most comprehensive and inclusive collection of hospi-
talization data available for the U.S. population. The insti-
tutional review board at the University of Virginia deter-
mined that this study does not meet the regulatory
definition of research involving human subjects (due to the
absence of patient identifiers in the data and the fact that
the data set is assembled for purposes other than research).
Therefore, no formal review is required.
Subject selection. Patients with CEA were identified
by searching the 2005NIS for all hospital discharge records
with an International Classification of Disease-Ninth Revi-
sion, Clinical Modifications (ICD-9-CM) procedure code
38.12 (CEA) listed as the primary procedure. Patients with
CEAwere included in the study population only if they also
had an accompanying ICD-9-CM diagnosis code indicat-
ing occlusion and stenosis of precerebral arteries (433.1).
Patients were excluded from the study population if they
had ICD-9-CM procedure codes during the same hospital-
ization for open chest coronary artery angioplasty (36.03),
bypass for heart revascularization (366.11-366.19), heart
revascularization by arterial implant (36.21-36.29), other
heart revascularization (36.31-36.39), other operation on
vessels of the heart (36.9), open heart valvuloplasty (35.10-
35.14), replacement of heart valve (35.20-35.28), or for
operations on structures adjacent to the heart valves
(35.31-35.39). Patients with these concurrent open cardiac
procedures were excluded because they are not representa-
tive of the patients who most commonly undergo CEA,
due to the much higher risk of death and stroke associated
with combined cerebrovascular and open cardiac proce-
dures.
Outcomes. The primary outcome of interest was the
occurrence of stroke or death during the patient’s hospital-
ization. Perioperative stroke was measured by identifying
all patients with an ICD-9-CM diagnosis code for iatro-
genic cerebrovascular infarction or hemorrhage (997.02);
this is a condition distinct from stroke-related events occur-
ring before the patient’s hospitalization. Death occurring
during the in-patient stay was identified from patient dis-
charge status. Stroke and death outcomes were combined
so that patients with both complications were only counted
once.Patient characteristics. Patients were classified as
symptomatic if they had an ICD-9-CM diagnosis code
identifying carotid artery occlusion with cerebral infarction
(433.11), had transient cerebral ischemia (435.0-435.9),
or had any late effects specifically attributed to cerebrovas-
cular disease (438.1-438.9), including cognitive deficit,
aphasia, dysphasia, hemiplegia, monoplegia, other paralytic
syndromes, apraxia, dysphasia, ataxia, or vertigo.
Patients in the study population with AF were identi-
fied by finding all cases with a secondary diagnosis code of
AF (427.31). Information about patient age at the time of
CEA and patient gender was also collected from the hospi-
tal discharge record. Categories of comorbid disease were
measured for each patient using the method developed by
Elixhauser et al.13 The Elixhauser method has been dem-
onstrated to provide effective adjustments for mortality risk
in populations with cerebrovascular disease.14,15 The Elix-
hauser method category for ‘paralysis’ was excluded from
our analysis. This category is identified by cerebrovascular
disease-related diagnoses that are not comorbid diseases in
our study population.
Statistical methods. Multiple logistic regression was
used to calculate the odds of death or stroke associated with
AF, adjusted for differences in patient age, gender, symp-
tomatic status, and for categories of comorbid disease. The
model included appropriate adjustments for variance com-
ponents estimated from the weighted study population.16
The statistical significance of the association between
AF and death or stroke was assessed using the Wald 2 test
statistic. Confidence intervals for the odds ratio estimated
for AF and for all other covariates in the multivariable
model were calculated using an alpha of 0.05. The capacity
of the model to discriminate was measured using the C
statistic and was validated using randomly split halves.
One-half of the data were used to estimate the model
equation. This equation was then applied to the reserved
half of the data to assess validated model discrimination.
The Hosmer-Lemeshow test was performed to assess the
statistical significance of differences in the model’s calibra-
tion across deciles of observed and predicted risk.
Sensitivity tests. One potential limitation of the anal-
ysis is the combined primary outcome measure of stroke or
death. The observed effect of AF could be sensitive to this
combined outcome measure, because the effect on stroke
could be different than the effect on death. To assess this
potential, two additional multivariable logistic regression
models were estimated: one to assess the effect of AF on
stroke outcomes only and another to assess the effect on
death only. Results for these two models were then com-
pared to the results from the primary outcome to assess
whether the effect was different for these components of
the combined outcome measure.
Another potential limitation is that the estimated effect
of AF on stroke and death could be a spurious result,
reflecting the influence of a closely related but unmeasured
confounder. To address this potential, a covariate that
identified patients with acute myocardial infarction (AMI;
ICD-9-CM code 410.00) was added to the original model.
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cation resulting from the myocardial event, such that AF
may function as a surrogate marker for the effects of the
AMI. Adding adjustments for the effects of AMI to the
original model provides a test of this potential limitation.
The potential for spurious results is reduced if the originally
observed effect is not substantially attenuated and remains
statistically significant when re-estimated with adjustments
for the concurrent effects of AMI.
The ICD-9-CM diagnosis code used to identify pa-
tients with AF includes some patients who experienced AF
as a complication during their hospitalization. Although AF
is a chronic, comorbid condition for most patients, includ-
ing patients who experienced AF as a complication could
produce a bias in the estimated effect. To address this
potential, we randomly selected a percentage of the patients
with AF, assuming that AF was a complication of surgery.
We changed these randomly selected cases in our measure
of AF to indicate that they did not have AF as a chronic
condition and developed a separate variable identifying
these patients as having AF as a complication of surgery.We
then re-estimated the multivariable logistic regression
model to calculate the statistical significance of the adjusted
odds of stroke or death associated with AF, using our
reduced measure of AF, including an additional covariate
identifying patients with AF as a complication of surgery.
The model was iteratively re-estimated in this manner,
converting increasingly larger proportions of the study
population with AF as a chronic condition to patients with
AF as a complication, to determine the proportion of
patients with AF in the original study population that could
be reassigned to having AF as a complication without
changing the statistical significance of the original model
result (at the P  .01 level).
RESULTS
The 2005 NIS data included 20,022 records for pa-
tients with CEA. There were 189 patients (0.94%) with
stroke, 59 (0.29%) with in-hospital death, and 18 with both
stroke and subsequent in-hospital death. A total of 230
patients (1.15%) had the combined outcome of stroke or
death. There were 1451 patients (7.2%) with AF, and 41 of
the 230 patients (17.8%) with stroke or death had AF.
Frequencies for all the patient characteristics included in
this analysis are listed in Table I, for the total population, by
outcome (stroke or death, and stroke and death), and for
patients with and without AF. The mean length of stay was
2.5 days (SD 3.2), and the median length of stay was 1.0
day (interquartile range  1-2). The mean length of stay
was 9.8 days among patients with either stroke or death,
compared to the average length of stay of 2.4 days for all
other patients, and this difference was highly statistically
significant (t test statistic P  .0001).
Results for the multivariable logistic regression analy-
ses, including the estimated odds of stroke or death for each
covariate included in each of the three models along with
their 95% confidence intervals, are listed in Table II. All
prespecified adjustment variables, including nonsignificantvariables, were retained in the final model, except variables
that did not have any cases among patients with the esti-
mated outcome.
Patients with AF had over twice the odds of death or
stroke (OR 2.45) compared to patients without AF, after
adjusting for the concurrent effects of differences in patient
age, gender, and for categories of comorbid disease. The
adjusted odds ratio for the effect of AF on the risk of stroke
or death was highly statistically significant (P .0001). The
multivariable logistic regression model demonstrated ade-
quate discrimination (C statistic  0.69) in the validation
data set. The model was well calibrated, obtaining a non-
significant (P  .3095) Hosmer-Lemeshow test value of
9.4018 with 8 degrees of freedom, indicating there was no
significant difference in fit across deciles of predicted risk.
The results were not sensitive to the combined end-
point of stroke or death. Patients with AF had statistically
significant higher odds of stroke only (OR  2.25; P 
.0003) and also of death only (OR  2.94; P  .0021)
when the original model was applied to estimate the odds
for the two outcomes separately.
Age, coagulopathy, and electrolyte abnormalities were
also statistically significant predictors of the combined
death and stroke outcome and of death and stroke as
separate outcomes. Alcohol abuse and chronic blood loss
anemia were statistically significant predictors of stroke, and
neurologic disorders (other than cardiovascular accident
[CVA]), chronic pulmonary disease, diabetes with compli-
cations, chronic weight loss, congestive heart failure, and
chronic blood loss anemia were statistically significant pre-
dictors of death.
There were 150 patients with AMI in the study popu-
lation. An AF was far more common among patients with
AMI (24.0%) than among those without (7.1%). The com-
bined outcome of death or stroke also occurred more often
among patients with AMI (10.0%) than among those with-
out AMI (1.1%). Re-estimation of the odds of stroke or
death for patients with AF with adjustment for the concur-
rent effect of AMI along with all of the other covariates in
the original model did not substantially attenuate the orig-
inal results. Patients with AMI had more than six times the
odds of stroke or death (OR  6.75; P .0001) as that of
patients without AMI, adjusted for the effects of all other
covariates in the original model. In the re-estimated model,
patients with AF had nearly the same adjusted odds of
stroke or death (OR 2.31; P .0001) as that obtained by
the original model without adjustments for AMI.
A minority of patients who experience AF as a compli-
cation (not a chronic condition) are included in the study
population. However, the adjusted odds ratio obtained for
the effect of AF on the risk of stroke or death is not likely to
be sensitive to including these patients. Simulation results
demonstrated that up to 50% of the patients with AF
included in the original study population could be ran-
domly converted to having AF as a complication, and the
adjusted odds ratio for the effect of AF on the risk of stroke
or death would still be statistically significant (OR  2.17;
P  .003) at the prespecified threshold (P  .01).
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This is the first report designed to primarily explore
the relationship between AF and adverse outcomes of
death and/or stroke during the same hospitalization
after CEA in the general population. In this study of
United States patients receiving CEA in 2005, those
with AF had over twice the odds of stroke or death, after
adjusting for differences in their age, gender, symptom-
atic status, and comorbid disease. This finding may be an
important starting point for eventual reduction in peri-
operative risk for patients with AF undergoing CEA. It
also identifies AF as an important variable that should be
analyzed in future research directed at the outcomes of
interventions for extracranial carotid stenosis, including
CEA and carotid artery stenting.
An AF may be caused by a range and variety of cardiac
Table I. Frequency distribution of patient characteristics b
Total
population
(% or mean)
Str
or d
(% or m
Stroke or death 1.1 100
Stroke 0.9 82
Death 0.3 25
Discharge routine 90.4 24
Discharged to short-term hospital 0.2 1
Discharged to skilled nursing facility 4.2 41
Discharged to home health 4.9 7
Atrial fibrillation 7.2 17
Age (years) 71.0 71
Symptomatic 10.2 27
Length of stay (days) 2.5 9
Female 43.0 44
Congestive heart failure 6.3 11
Valvular disease 6.2 6
Pulmonary circulatory disease 0.6 0
Peripheral vascular disease 18.7 17
Hypertension 76.3 71
Neurologic disorder (other than CVA) 0.1 0
Chronic pulmonary disease 20.1 23
Diabetes mellitus without complication 26.2 26
Diabetes mellitus with complication 2.5 2
Hypothyroidism 8.9 9
Renal failure 2.9 4
Liver disease 0.3 0
Peptic ulcer with bleeding 0.1 0
Acquired immunodeficiency syndrome 0.1 0
Lymphoma 0.3 0
Metastatic cancer 0.2 0
Solid tumor without metastasis 1.0 0
Arthritis or collagen vascular disorder 1.4 1
Coagulopathy 0.7 3
Obesity 4.6 3
Chronic weight loss 0.3 2
Fluid and electrolyte disorders 3.9 1
Chronic blood loss anemia 0.3 0
Deficiency anemia 4.6 7
Alcohol abuse 0.9 3
Drug abuse 0.1 0
Psychoses 0.5 0
Depression 3.9 3
CVA, Cardiovascular accident.diseases. These can include lone AF (no structural cardiacdisorder identified) to significant ischemic or valvular dis-
ease. Multiple medical problems can be associated with
chronic AF including thromboembolism, sleep apnea, stiff
ventricle, and congestive heart failure. This association may
help explain the increased mortality that we found in this
group of patients. An AF has been shown to be a marker for
increased mortality in a number of other conditions.17 The
association with stroke is not so easily explained. Patients
with AF and patients with carotid stenosis each have in-
creased long-term stroke risk when compared to a nonaf-
fected population.
An AF is the cause of significant morbidity and
mortality related to the formation of thrombus in the
cardiac atria, and its subsequent expulsion by the ventri-
cle to a long list of potential end-organs. Because of this
potential, many people with chronic AF receive antico-
oke or death, stroke, death, and by atrial fibrillation
)
Stroke
(% or mean)
Death
(% or mean)
No atrial
fibrillation
(% or mean)
Atrial
fibrillation
(% or mean)
100.0 100.0 1.0 2.8
100.0 30.5 0.9 2.0
9.5 100.0 0.2 1.2
29.6 0.0 91.2 79.5
1.6 0.0 0.2 0.6
50.8 0.0 3.8 9.0
8.5 0.0 4.5 9.7
15.3 28.8 0.0 100.0
71.4 73.1 70.6 75.9
24.3 33.9 10.1 11.8
8.8 13.8 2.4 4.2
45.5 39.0 43.2 40.3
8.5 25.4 5.3 19.5
6.3 5.1 5.5 14.6
0.0 0.0 0.5 2.3
17.5 18.6 18.8 18.4
74.6 57.6 76.5 73.9
0.5 0.0 0.1 0.1
19.6 47.5 19.7 24.1
26.5 25.4 26.3 26.1
3.2 0.0 2.5 2.6
9.0 6.8 8.7 10.9
3.7 8.5 2.9 3.3
0.0 1.7 0.4 0.2
0.0 0.0 0.1 0.0
0.0 0.0 0.1 0.0
0.5 0.0 0.3 0.3
0.0 1.7 0.2 0.2
0.5 1.7 1.0 0.9
1.6 1.7 1.4 1.4
2.6 13.6 0.7 1.7
4.2 3.4 4.7 4.5
1.1 8.5 0.3 0.5
10.1 32.2 3.7 6.7
0.0 3.4 0.3 0.5
6.3 11.9 4.4 6.0
3.2 3.4 0.9 0.6
0.0 0.0 0.1 0.1
0.0 0.0 0.5 0.3
2.1 6.8 4.0 3.2y str
oke
eath
ean
.0
.2
.6
.4
.3
.7
.0
.8
.6
.4
.8
.3
.7
.1
.0
.8
.7
.4
.5
.1
.6
.1
.8
.4
.0
.0
.4
.4
.9
.7
.9
.5
.6
.1
.9
.4
.0
.0
.0
.5agulant medication to prevent the formation of intracar-
for pa
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discontinue their anticoagulation and start antiplatelet
medication if they are not already receiving antiplatelet
medication. This transition is typically recommended to
occur in less than 7 days.18 The higher adverse outcomes
of CEA in patients with AF may be due to chronic use of
medications such as warfarin, that have been reported to
increase plaque instability,19 therefore rendering these
patients at higher risk of atheroembolism and stroke
during CEA. Similarly, it is possible that the commence-
ment of drugs such as aspirin only 5 days before surgery
is too short a time to realize the known protective
benefits during the perioperative period.
Characteristics of the administrative data used in this
study limit the results in several aspects. Our results under-
estimate the true perioperative death and/or stroke rate.
Table II. Multivariable logistic regression model results
Stroke or death
Adjusted OR
(95% CI) P value
Atrial fibrillation 2.45 (1.67-3.59) .0001
Age (years) 3.07 (2.25-4.17) .0001
Symptomatic 1.00 (0.99-1.02) .9524
Female 1.05 (0.80-1.37) .7499
Congestive heart failure 1.41 (0.90-2.22) .1350
Valvular disease 0.78 (0.44-1.39) .3980
Pulmonary circulatory disease N/A N/A
Peripheral vascular disease 0.97 (0.69-1.38) .8827
Hypertension 0.80 (0.60-1.06) .1214
Neurologic disorder (other
than CVA) 2.80 (0.27-28.78) .3869
Chronic pulmonary disease 1.10 (0.81-1.49) .5601
Diabetes mellitus without
complication 1.03 (0.76-1.41) .8428
Diabetes mellitus with
complication 0.88 (0.35-2.21) .7846
Hypothyroidism 1.05 (0.66-1.66) .8458
Renal failure 1.10 (0.55-2.21) .7920
Liver disease 0.73 (0.08-6.45) .7796
Peptic ulcer with bleeding N/A N/A
Acquired immunodeficiency
syndrome N/A N/A
Lymphoma 1.01 (0.12-8.60) .9929
Metastatic cancer 1.88 (0.22-16.02) .5620
Solid tumor without metastasis 0.82 (0.19-3.47) .7822
Arthritis or collagen vascular
disorder 1.05 (0.38-2.89) .9272
Coagulopathy 3.97 (1.96-8.05) .0001
Obesity 0.74 (0.35-1.54) .4222
Chronic weight loss 4.67 (1.63-13.37) .0041
Fluid and electrolyte disorders 2.87 (1.88-4.40) .0001
Chronic blood loss anemia 2.26 (0.56-9.21) .2548
Deficiency anemia 1.30 (0.76-2.23) .3368
Alcohol abuse 2.67 (1.09-6.55) .0318
Drug abuse N/A N/A
Psychoses N/A N/A
Depression 0.87 (0.42-1.8) .7095
OR, Odds ratio; CI, confidence interval; CVA, cardiovascular accident; N/
N/A indicates that the odds ratio estimate was not applicable for this variab
calculated for these covariates, because there were no cases of the covariateWe were not able to identify deaths occurring after patientswere discharged from the hospital, because the NISHCUP
data does not include information about patient survival
postdischarge. We also were unable to identify strokes
occurring after discharge, because the NIS HCUP data do
not include unique patient identifiers required for identify-
ing subsequent stroke-related hospitalization.
Characterization of AF is limited in this analysis to the
presence or absence of the diagnosis. The status of patient
with AF at the time of surgery cannot be specified. For
example, there is no information in the available data to
indicate whether the patient was in AF at the time of
surgery, or if the patient was in sinus rhythm with a history
of AF. Whether AF was a chronic condition occurring
before the CEA, or a postoperative complication, also
cannot be determined with the available data. However,
the potential effect of misclassification of AF was tested
Stroke Death
Adjusted OR
(95% CI) P value
Adjusted OR
(95% CI) P value
.25 (1.44-3.51) .0003 2.94 (1.48-5.84) .0021
.69 (1.89-3.83) .0001 3.84 (2.1-6.99) .0001
.00 (0.98-1.02) .9776 1.01 (0.98-1.05) .4455
.15 (0.86-1.55) .3464 0.68 (0.39-1.2) .1849
.08 (0.61-1.9) .7957 2.32 (1.1-4.9) .0266
.90 (0.48-1.67) .7336 0.45 (0.12-1.62) .2208
N/A N/A N/A N/A
.96 (0.66-1.41) .8465 0.97 (0.46-2.03) .9363
.91 (0.66-1.26) .5689 0.44 (0.26-0.76) .0031
.91 (0.41-37.48) .2368 N/A .0001
.91 (0.63-1.3) .5931 2.98 (1.7-5.24) .0001
.03 (0.74-1.44) .8499 1.13 (0.57-2.21) .7298
.18 (0.48-2.94) .7181 N/A .0001
.04 (0.63-1.71) .8819 0.77 (0.25-2.42) .6554
.96 (0.41-2.26) .9266 1.54 (0.55-4.32) .4150
N/A N/A 3.05 (0.22-42.9) .4094
N/A N/A N/A N/A
N/A N/A N/A N/A
.44 (0.18-11.36) .7273 N/A N/A
N/A N/A 4.23 (0.27-65.44) .302
.51 (0.07-3.79) .5125 1.38 (0.18-10.74) .7593
.98 (0.3-3.2) .9766 0.95 (0.13-6.94) .9629
.79 (1.11-7.01) .0295 14.19 (6.19-32.5) .0001
.91 (0.44-1.89) .7956 0.66 (0.13-3.28) .6077
.70 (0.36-8.01) .4996 13.36 (3.46-51.55) .0002
.13 (1.26-3.62) .0048 7.24 (3.69-14.18) .0001
N/A .0001 6.93 (1.32-36.48) .0224
.21 (0.65-2.24) .5525 1.69 (0.66-4.27) .2718
.33 (1.37-8.12) .008 1.17 (0.12-11.17) .8922
N/A N/A N/A N/A
N/A N/A N/A N/A
.50 (0.18-1.38) .1791 2.35 (0.82-6.71) .1117
applicable.
that the variable was excluded from the final model. Odds ratios were not
tients with the outcome being predicted.2
2
1
1
1
0
0
0
3
0
1
1
1
0
1
0
0
2
0
1
2
1
3
0
A, not
le andusing simulation. These sensitivity tests demonstrate that
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condition can be randomly converted to having AF as a
complication before the observed association between AF
and stroke or death is no longer statistically significant.
Another limitation of the analysis is the potential role of
unmeasured confounders. We were unable to include ad-
justments for many factors known to contribute to mortal-
ity and stroke risk, including degree of stenosis and status of
the contralateral carotid artery. These and other known risk
factors for perioperative death and stroke may occur more
or less frequently among patients with AF, and this differ-
ence could bias the results. However, the analysis demon-
strates that the observed association between AF and stroke
or death is resilient to the potential presence of an unmea-
sured confounder. When adjustments for the effects of a
highly predictive covariate (AMI) are added to the multi-
variable logistic regression model, patients with AF still
have statistically significant increased risk of stroke and/or
death. Also, McGirt et al10 analyzed risk factors to deter-
mine the effect of 3-hydroxy-3-methylglutaryl coenzyme A
reductase inhibitors on outcomes of CEA.10 This analysis
included AF as a separate variable and was performed on
data obtained directly from hospital charts. An AF identi-
fied in their study represented only chronic AF and not
new-onset AF. The rate of chronic AF in their CEA popu-
lation was 4%,10 which is similar to the rate of AF in our
NIS population (7%), implying that AF as an acute
complication during CEA is probably relatively rare and
likely does not represent a significant proportion of the
patients we studied.
Several categories of comorbid disease included in the
risk adjustment model were highly statistically significant
predictors of stroke and/or death. For example, patients
identified with coagulopathy had nearly four times the risk
of stroke and/or death (OR  3.9; 95% CI, 1.9-8.1).
Patients identified with ‘coagulopathy’ included individuals
with congenital clotting factor disorders, acquired clotting
factor deficiency, thrombocytopathy, primary and second-
ary thrombocytopenia, primary and secondary hypercoag-
ulable state, ecchymoses, and coagulation deficiency asso-
ciated with childbirth. Although the association is highly
statistically significant, the specific nature of this association
is difficult to discern because ‘coagulopathy’ is broadly
defined. Some of the observed association between stroke
and death may be attributable to atrial thrombus occurring
among relatively hypercoagulable patients, since this cate-
gory includes patients receiving anticoagulant therapy be-
fore surgery, although these patients cannot be separately
identified in the available data.
The classification of preoperative neurologic symptoms
is another limitation. If the patient had symptoms (stroke,
transient ischemic attack, or amarosis fugax) related to the
carotid stenosis before surgery, it is possible to determine if
these symptoms predate the surgery as we have done but
impossible to ascertain if the symptom occurred in the same
cerebral hemisphere as the carotid lesion that was treated or
to determine the timing of those symptoms. The degree of
stenosis and status of the contralateral carotid artery is alsounavailable in this data source. Important technical aspects
of the surgery (use and type of patch20,21 or shunt) and use
of adjunctive medications (antiplatelet agents,22 beta-
blockers,23-25 and cholesterol-lowering medications10) are
also unknown. All of these aspects of carotid artery surgery
have been demonstrated to have some impact on out-
comes.
The overall efficacy of CEA in this higher-risk popula-
tion is unknown. It should be noted that the combined
stroke and death rate among the 1451 patients with a
diagnosis code of AF was 2.8%. It is possible that patients
with AF and a high-grade carotid stenosis may have an even
higher rate of stroke and death with medical management,
which would imply that CEA is still the therapy of choice. It
is premature, based on the data presented here, to withhold
CEA altogether from patients with AF.
The demonstrated association between AF and adverse
outcomes in CEA is an important and clinically relevant
discovery. This study indicates that special attention should
be paid to preoperative evaluation and counseling of pa-
tients with AF. In addition, further scientific evaluation of
this association is warranted. Consideration should be
given to include AF as an important risk factor in ongoing
clinical trials for the treatment of carotid artery stenosis.
Although the administrative data have limitations, as de-
tailed above, and cannot answer the question of why AF is
related to poor outcomes after CEA, this study provides the
high volume of observations necessary to assess the effects
of risk factors for infrequent outcomes such as death and
stroke after CEA. Continued exploration of the relation-
ship of AF to major adverse events after CEA may lead to a
better understanding of the etiology of this relationship
and to improvements in treatment for patients with AF and
carotid artery stenosis.
The authors had full access to all of the data in the study
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